1. Executive Summary

The National Institute for Health and Care Excellence (NICE) is the independent body that provides evidence-based guidelines and recommendations on which treatments, drugs, and procedures should be available within the NHS.

 "NICE is the NHS's rational gatekeeper. It asks two questions: 'Does this treatment work?' and 'Is it worth the money?' – because the NHS has finite resources and must spend them where they do the most good."

2. What Does NICE Do? (The Three Core Functions)

2.1 Clinical Guidelines

• Evidence-based recommendations on how to diagnose, manage, and treat specific conditions (e.g., asthma, diabetes, depression).

• Aim to standardise care – so a patient in Cornwall receives the same quality of care as a patient in Cumbria.

2.2 Technology Appraisals (Most Famous/Controversial)

• Evaluates new drugs, devices, and procedures.

• Decides whether the NHS should fund them.

• Uses the QALY (Quality-Adjusted Life Year) to assess cost-effectiveness.

2.3 Quality Standards

• Sets measurable, ambitious markers of high-quality care.

• Used by the CQC to inspect services.

3. The QALY – NICE's Most Important (and Most Controversial) Tool

3.1 What is a QALY?

Term Definition

QALY Quality-Adjusted Life Year – one QALY equals one year of life in perfect health.

How it works A treatment that gives a patient 1 extra year of perfect health = 1 QALY. A treatment that gives 2 extra years but with reduced quality (e.g., pain, disability) = less than 2 QALYs.

3.2 How NICE Uses QALYs

NICE typically considers a treatment cost-effective if it costs less than £20,000–£30,000 per QALY gained.

Cost per QALY NICE Decision

Less than £20,000 Usually approved (good value).

£20,000 – £30,000 Approved if there are strong reasons (e.g., end-of-life, rare disease).

More than £30,000 Usually rejected unless exceptional circumstances.

More than £50,000 Almost always rejected (not cost-effective).

Example:

• Drug A costs £10,000 and gives 1 extra QALY = £10,000/QALY → approved.

• Drug B costs £100,000 and gives 2 extra QALYs = £50,000/QALY → likely rejected.

3.3 Visual: QALY Calculation

4. Why Does NICE Matter? (The Ethical and Practical Case)

Interview Hook: "Without NICE, the NHS would be unable to make rational decisions about which new drugs to fund. Every new cancer drug, every expensive device – someone has to say no. NICE does that transparently and based on evidence, not politics."

5. How NICE Guidelines Are Developed (The Process)

This shows you understand the rigour behind the guidelines.

Key Point for Interview: *"NICE guidelines are not static. They are updated as new evidence emerges – for example, COVID-19 guidelines changed rapidly as the science evolved."*

6. Key NICE Guidelines You Should Know (For Interview Examples)

6.1 Antimicrobial Resistance (AMR)

Interview Example: "NICE's guidelines on antimicrobial resistance recommend that doctors should not prescribe antibiotics for self-limiting viral infections like sore throats or acute otitis media. This protects patients from side effects and slows the development of resistance – a clear example of non-maleficence (do no harm) at a population level."

6.2 End-of-Life Care

Interview Example: "NICE's end-of-life care guidelines emphasise patient autonomy. A terminally ill patient with capacity has the right to refuse life-prolonging treatment and focus on comfort. NICE provides evidence-based recommendations on symptom control – ensuring beneficence (managing pain) without violating autonomy."

6.3 Organ Donation (Opt-Out System)

Interview Example: "NICE supports the UK's opt-out organ donation system by providing evidence on how to maximise donations while respecting donor autonomy. This balances justice (more organs for waiting patients) with non-maleficence (not coercing donors)."

6.4 Expensive Cancer Drugs (e.g., Kymriah, CAR-T Therapy)

Interview Hook: "NICE often faces public criticism when it rejects a cancer drug. But the reality is that the NHS budget is finite. If NICE approved every drug regardless of cost, other services – like A&E, maternity, or mental health – would have to close. NICE's job is heartbreaking but necessary."

7. NICE and the Four Pillars of Medical Ethics

This is the highest-yield connection for interviews.

The Central Ethical Tension: NICE must balance individual beneficence (treating this patient with this expensive drug) against distributive justice (using the money to treat many patients with cheaper, effective treatments).

Model Sentence: "NICE operationalises the ethical principle of justice in a resource-limited system. The QALY is an imperfect tool – critics argue it discriminates against the elderly and disabled – but it is the best available method for transparent, consistent rationing decisions. Without NICE, rationing would happen randomly or politically, which would be less fair, not more."

8. Controversies and Criticisms of NICE (For Balanced Answers)

Strong candidates discuss limitations and controversies.

Interview Hook: "NICE is not perfect. The QALY has well-documented limitations – it tends to undervalue treatments for the elderly and disabled. But the alternative – no transparent rationing – would be worse. Patients would face hidden rationing via long waiting lists or postcode lotteries. At least NICE's decisions are public and appealable."

9. NICE vs. Other Regulators – Know the Difference

Key Distinction: The MHRA decides if a drug is safe and effective enough to be licensed. NICE decides if it is cost-effective enough to be funded by the NHS. A drug can be licensed by MHRA but rejected by NICE.

10. Four Interview Questions & Answers

Q1 (Easy): "What is NICE and what does it do?"

Answer:
"NICE – the National Institute for Health and Care Excellence – is the independent body that provides evidence-based guidelines and recommendations for the NHS. It has three main functions: producing clinical guidelines on how to diagnose and treat conditions, conducting technology appraisals to decide which new drugs and devices the NHS should fund, and setting quality standards. Its most famous tool is the QALY – the Quality-Adjusted Life Year – which measures the health benefit of a treatment relative to its cost. NICE typically approves treatments costing less than £20,000–£30,000 per QALY."

Summary

• NICE = National Institute for Health and Care Excellence
• Independent organisation providing evidence-based guidance for the NHS
• Promotes safe, effective, and cost-effective healthcare
• Develops clinical guidelines for diagnosis and treatment
• Conducts technology appraisals for new drugs and medical devices
• Produces quality standards for healthcare services
• Provides public health guidance
• Uses QALYs (Quality-Adjusted Life Years) to assess value of treatments
• QALY combines:
• • Length of life gained
  • Quality of life gained
• Helps determine whether treatments are cost-effective
• Treatments costing around £20,000–£30,000 per QALY are often considered cost-effective
• Supports evidence-based decision making
• Helps ensure consistent care across the NHS
• Assists with fair allocation of NHS resources
• Influences which medicines and treatments are funded by the NHS

Q2 (Medium): "How does NICE balance cost-effectiveness with ethical patient care?"

Answer (using the 4 pillars):
"NICE faces an inherent ethical tension between beneficence (doing good for an individual patient) and justice (fair distribution of limited resources). Its QALY system attempts to balance these by measuring the health gain from a treatment and comparing it to its cost.

*For example, a drug that costs £100,000 per QALY would normally be rejected. That decision harms the small number of patients who could benefit – a violation of individual beneficence. But approving it would mean denying other, more cost-effective treatments to many more patients – a violation of distributive justice.*

NICE tries to resolve this through transparency (publicly explaining its decisions) and exceptions (e.g., end-of-life criteria allow higher thresholds for very small populations). It is not perfect, but it is more ethical than hidden rationing or political decisions."

Q3 (Hard): "Critics say the QALY discriminates against elderly and disabled people. Do you agree?"

Answer:
"I understand the criticism. The QALY gives more weight to treatments that extend life in younger, healthier patients – because they have more years left to gain, and their quality of life is weighted higher. An elderly patient with multiple comorbidities may generate fewer QALYs from the same treatment.

*However, I think the criticism is partly misunderstanding. The QALY does not say that elderly or disabled lives are 'worth less' as people. It is a measure of health gain from a specific treatment. An 85-year-old may gain 0.5 QALYs from a hip replacement; a 50-year-old may gain 1.5 QALYs. That does not mean the 85-year-old is less valuable – it means the treatment has less impact because they have fewer years left.*

*That said, NICE has recognised the concern. It introduced 'end-of-life' criteria, allowing treatments for patients with very short life expectancy (less than 24 months) to be approved at higher cost-per-QALY thresholds. This partially addresses the concern for the elderly and terminally ill. No system is perfect, but I believe the QALY is the best available tool for transparent, consistent rationing."

Summary

• QALYs are sometimes criticised for favouring younger, healthier patients
• Younger patients often have more years of life to gain
• The same treatment may generate more QALYs in younger people
• Elderly patients and those with multiple comorbidities may gain fewer QALYs
• QALYs do not measure the value of a person
• QALYs measure health gain from a specific treatment
• They assess the impact of an intervention, not a person's worth
• Example:
• • 85-year-old hip replacement → fewer QALYs gained
  • 50-year-old hip replacement → more QALYs gained
  • Reflects difference in health benefit, not patient value
• NICE recognises concerns about age and fairness
• Introduced End-of-Life Criteria
• Allows higher cost-per-QALY thresholds for some end-of-life treatments
• Typically applies to patients with a life expectancy of less than 24 months
• Advantages of QALYs:
• • Transparent decision-making
  • Consistent framework
  • Supports fair allocation of NHS resources
  • Allows comparison between different treatments
• Limitations:
• • May not capture all social and personal benefits
  • Ethical concerns remain regarding age, disability, and equity
  • No rationing system is perfect
• Key point: QALYs measure health benefit, not human value.

Q4 (Hard): "A patient asks you for a treatment that is not recommended by NICE because it is not cost-effective. What do you do?"

Answer (using SEARCH framework):

"First, I would seek information – why does the patient want this specific treatment? Have they read about it online? Is it their only hope? I would also check if there are any exceptional circumstances that might justify an Individual Funding Request (IFR) outside NICE guidance.

Second, I would show empathy – I understand that when you or a loved one is seriously ill, you want every possible option. I would not dismiss their request dismissively.

Third, I would take action by explaining the situation honestly but sensitively. I would say: 'NICE has reviewed this treatment and decided that the evidence of benefit does not justify the cost to the NHS. I cannot prescribe it on the NHS, but I can explain why NICE made that decision, and I can support you in making an Individual Funding Request if appropriate.'

Fourth, I would discuss the response – the patient may wish to self-fund the treatment privately. I would not discourage that, but I would ensure they understand the risks and lack of NHS support.

Fifth, I would consider consequences – if I prescribe a non-NICE-approved treatment without exceptional approval, I would be violating NHS policy and potentially denying resources to other patients (a justice issue).

Finally, I would aim to prevent harm – ensuring the patient does not feel abandoned or dismissed, even though I cannot give them what they want. I would signpost to palliative care, clinical trials, or second opinions if appropriate.

This approach respects patient autonomy while upholding my professional duty to use NHS resources fairly."

Common Interview Questions

Easy

• What is NICE?
• What does NICE do?
• What is a QALY?
• How are NICE guidelines developed?

Medium

• How does NICE balance cost-effectiveness with patient care?
• Why are NICE guidelines important for doctors?
• How does NICE address antimicrobial resistance?
• How does NICE influence end-of-life care?

Hard / Advanced

• Critics say QALYs discriminate against elderly and disabled people. Do you agree?
• Should NICE ever approve a treatment costing more than £50,000 per QALY?
• How would you handle a patient requesting a non-NICE-approved treatment?
• Is it ethical for NICE to say "no" to life-extending cancer drugs?

11. Quick Revision Table

12. Ultimate Interview Tip – How to Turn a Good Answer into a Great One

Formula for distinction: *Define NICE → Explain key functions → Introduce QALY with threshold → Apply to real example (AMR/end-of-life) → Discuss ethical tensions (4 pillars) → Acknowledge criticisms → State balanced conclusion.

Useful Links

https://www.nice.org.uk/

https://www.nice.org.uk/guidance

https://www.nice.org.uk/about/what-we-do

https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance

https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance

https://www.nice.org.uk/process/pmg20

https://www.nice.org.uk/standards-and-indicators

https://pathways.nice.org.uk/

https://www.nice.org.uk/guidance/conditions-and-diseases